Combination of immunotherapy with targeted therapy: theory and practice in metastatic melanoma
- 1State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, China
- 2Department of Liver Surgery, Liver Transplantation Center, West China Hospital, Sichuan University, China
Metastatic melanoma is the most aggressive and obstinate skin cancer with poor prognosis. Variant novel applicable regimens emerged during the past decades intensively, while the most profound approaches are oncogene-targeted therapy and T-lymphocyte mediated immunotherapy. Although targeted therapies generated remarkable and rapid clinical responses in the majority of patients, acquired resistance was developed promptly within months leading to tumor relapse. By contrast, immunotherapies elicited long-term tumor regression. However, the overall response rate was limited. In view of the above, either targeted therapy or immunotherapy cannot elicit durable clinical responses in large range of patients. Interestingly, the advantages and limitations of these regimens happened to be complementary. An increasing number of preclinical studies and clinical trials proved a synergistic antitumor effect with the combination of targeted therapy and immunotherapy, implying a promising prospect for the treatment of metastatic melanoma. In order to achieve a better therapeutic effectiveness and reduce toxicity in patients, great efforts need to be made to illuminate multifaceted interplay between targeted therapy and immunotherapy.
Keywords: Immunotherapy, Immune checkpoint blockade, Metastatic Melanoma, targeted therapy, combinatorial regimens
Received: 16 Oct 2018;
Accepted: 16 Apr 2019.
Edited by:Zhihai QIN, Institute of Biophysics (CAS), China
Reviewed by:Yuting MA, Center of Systems Medicine, Chinese Academy of Medical Sciences, Suzhou Institute of Systems Medicine (ISM), China
Ying Du, Zhengzhou University, China
Copyright: © 2019 Yu, Shi, Ma, Liu, Yang, Zhang and Jin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Prof. Hubing Shi, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China, firstname.lastname@example.org
Dr. Xuelei Ma, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China, email@example.com